SG Americas Securities
SYRE icon

SG Americas Securities’s Spyre Therapeutics SYRE Stock Holding History

SG Americas Securities’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
12,727
-669
-5% -$48.8K ﹤0.01% 1801
2026
Q1 		$676K Sell
13,396
-9,947
-43% -$375K ﹤0.01% 2007
2025
Q4 		$765K Buy
+23,343
New +$610K ﹤0.01% 2228
2025
Q2 		– Sell
-7,122
Closed -$115K – 3569
2025
Q1 		$115K Buy
+7,122
New +$148K ﹤0.01% 2943
2024
Q4 		– Sell
-12,589
Closed -$370K – 3600
2024
Q3 		$370K Buy
12,589
+7,044
+127% +$196K ﹤0.01% 1956
2024
Q2 		$130K Buy
+5,545
New +$187K ﹤0.01% 2404
2022
Q3 		– Sell
-713
Closed -$9K – 3548
2022
Q2 		$9K Buy
+713
New +$25K ﹤0.01% 3372
2022
Q1 		– Sell
-441
Closed -$52K – 3413
2021
Q4 		$52K Sell
441
-702
-61% -$111K ﹤0.01% 3185
2021
Q3 		$227K Buy
+1,143
New +$200K ﹤0.01% 3144
2020
Q3 		– Sell
-916
Closed -$212K – 3417
2020
Q2 		$212K Buy
916
+499
+120% +$95K ﹤0.01% 2816
2020
Q1 		$49K Buy
+417
New +$70.9K ﹤0.01% 3182

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SG Americas Securities's SYRE Position: Q2 2026 in Review

SG Americas Securities reduced its Spyre Therapeutics (SYRE) stake by 5% in Q2 2026, selling an estimated $48.8K and leaving 12,727 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1801.

SG Americas Securities first reported a position in SYRE in Q1 2020 and has held it in 11 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • SG Americas Securities held 12,727 shares of Spyre Therapeutics worth $1.13M as of Q2 2026.
  • SG Americas Securities sold 669 Spyre Therapeutics shares in Q2 2026, an estimated $48.8K.
  • Spyre Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1801 holding.
  • SG Americas Securities first reported a position in Spyre Therapeutics in Q1 2020 and has held it in 11 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.